Novo Nordisk partners with OpenAI in weight loss drug race
On Apr. 14, 2026, Novo Nordisk, the maker of popular weight-loss drugs Ozempic and Wegovy, is partnering with OpenAI…
-
-
Novartis to acquire Excellergy for $2 Billion, building on allergy leadership with next-generation anti-IgE innovation
On Mar. 27, 2026, Novartis announced an agreement to acquire Excellergy, a private biotech company developing next-generation anti-IgE…
-
DNA in dirt is shaking up the study of human origins
On Mar. 24, 2026, a study published in Nature describes how researchers are pulling clues from genetic material…
-
Biotechnology | CDC | Infectious Disease | NIH | Vaccine | WHO
Danish university places hold on controversial U.S. CDC hepatitis B vaccine study in Guinea-Bissau
On Mar. 19, 2026, the University of Southern Denmark announced it has placed a “full hold” on a…
-
Novo Nordisk announces more than 400 million euro expansion in its manufacturing facility in Ireland
On Mar. 2, 2026, Novo Nordisk announced an investment of 432 million euro (approx. DKK 3.2 billion) in…
-
Biotechnology | Disease | FDA
FDA approves Novo Nordisk’s Sogroya® as first and only once-weekly, long-acting growth hormone for three additional pediatric indications
On Feb. 27, 2026, Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved three…
-
FDA approves Novo Nordisk’s Wegovy® pill, the first and only oral GLP-1 for weight loss in adults
On Dec. 22, 2025, Novo Nordisk announced announced that the US Food and Drug Administration (FDA) has approved…
-
Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
On Dec. 18, 2025, Novo Nordisk announced the submission of a New Drug Application (NDA) to the U.S….
-
Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost
On Nov. 6, 2025, Novo Nordisk announced it has agreed with the U.S. Administration to lower drug prices…
-
Biotechnology | Disease | Infectious Disease | Influenza | Measles | Neurology | NIH | Vaccine
Large Danish Study Shows No link between vaccines and autism or 49 other health conditions
On Jul. 15, 2025, a new Danish study finds no association between aluminum in childhood vaccines and 50…
-
Psittacosis reported in European region
On Mar. 5, 2024, the World Health Organization (WHO) announced that in February 2024, Austria, Denmark, Germany, Sweden…
-
Biotechnology | Disease | FDA | Neurology | Therapeutics
FDA approved first drug to treat agitation symptoms associated with dementia due to Alzheimer’s disease
On May 11, 2023, the U.S. Food and Drug Administration (FDA) announced the supplemental approval of Otsuka Pharmaceutical…
-
COVID-19 | USDA | Veterinary
First case of SARS-CoV-2 in mink confirmed in Oregon
On Nov. 27, 2020, the U.S. Department of Agriculture (USDA) announced that it had confirmed cases of SARS-CoV-2…
-
FDA approved Novo Nordisk’s injection for obesity
On Dec. 23, 2014, the U.S. Food and Drug Administration (FDA) approved a formulation of Novo Nordisk’s diabetes drug, liraglutide,…
-
The first Ancient North American genome was sequenced
On Feb. 12, 2014, scientists, led by ancient DNA expert Eske Willerslev of the University of Copenhagen and…
-
ZymoGenetics was instrumental in development of new hemophilia drug
On Mar. 27, 1999, Novo Nordisk, the ZymoGenetics parent company, announced approval of NovoSeven by the Food and…
-
Biotechnology | Chemistry | Disease | FDA | Therapeutics
The Earl Davie/ZymoGenetics Endowed Chair of Biochemistry at the University of Washington was established
On Apr. 14, 1993, the Earl Davie/ZymoGenetics Endowed Chair of Biochemistry at the University of Washington was established…
-
mpox was first discovered
In 1958, mpox (MPVX) was first discovered when two nonfatal outbreaks of a pox-like disease were reported in…
